Vivos Therapeutics Inc   (VVOS)
Other Ticker:  


Vivos Therapeutics Inc

VVOS's Financial Statements and Analysis

Vivos Therapeutics Inc increased III. Quarter net loss per share of $-0.26 compare to net loss per share of $-0.26 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.33 realized in previous quarter.

III. Quarter
Earnings Per Share Revenues
$ -0.26 $  4 Mill
Unch.     Unch.     -6.6 %

Vivos Therapeutics Inc 's Revenue fell by -6.6 % in III. Quarter (Sep 30 2022) year on year, to $4 million and advanced by 1.48 % sequentially.

Vivos Therapeutics Inc is Expected to report next financial results on March 30, 2023.

More on VVOS's Income Statement

Vivos Therapeutics Inc 's in III. Quarter recorded net loss of $-5.434 million, an improvement compare to net loss of $-5.453 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-6.992 million realized in previous quarter.

More on VVOS's Growth

In III. Quarter company's net cash and cash equivalents decreased by $-6 million, capital expenditures grew by -77.30%, to $0 millions compare to same quarter a year ago and rose by -80.16% from II. Quarter (Jun 30 2022).

More on VVOS's Cash flow Statement

Vivos Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Vivos Therapeutics Inc payed $ -0.98 cash per share, on a free-cash flow basis .